BioSpace News Archive

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported that data supporting the role of CCL24 as a therapeutic target for systemic sclerosis (SSc) is being presented in a poster at the EULAR European Congress of Rheumatology this week.

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will host its Annual Meeting virtually on Tuesday, June 7, 2022 , at 10:00 a.m. Eastern.

EVERSANA™ announced the launch of an integrated learning and performance solution for life sciences professionals.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two fireside chats being webcast in June.

Round led by Northpond Ventures, with participation from Taiho Ventures, Bristol Myers Squibb, Lifeforce Capital and Magnetic Ventures.

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, is showcasing the use of its high-pressure mass spectrometry and microfluidics separation technologies in twelve presentations at the 70th American Society for Mass Spectrometry (ASMS) Conference June 5-9 in Minneapolis.

First-of-a-kind TOPS System designed to offer treatment alternative for patients with spinal stenosis and spondylolisthesis.

Deciphera Pharmaceuticals, Inc. announced that members of the management team will participate in fireside chats at the following investor conferences.

Data from AiKidney Helps Clinicians Gain New Insights into Patient’s Risk of Allograft Rejection.

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 2022 Jefferies Healthcare Conference, being held June 8-10, 2022 in New York, NY.